Most breakthrough therapies start with a hypothesis. Ours began with a question: Can a natural human protein protect cartilage from destruction?
What followed changed everything.
🔬 Act I: The In Vitro Spark
Years ago, our team conducted a deceptively simple experiment: we purified the Alpha-2-Macroglobulin (A2M) protein from human blood and added it to degraded cartilage in a petri dish.
The result? A2M significantly reduced the activity of cartilage-destroying proteases like ADAMTS-5 and MMP-13 — enzymes that play a key role in the progression of osteoarthritis.
This single experiment opened the door to a revolutionary idea: that A2M might not just slow OA, but could stop it at the source.
💡 Act II: From Blood to Blueprint
Inspired by this finding, we developed a therapy called APIC™ — a device that concentrates a patient’s own A2M from their blood and injects it directly into the joint. It went on to treat over 10,000 patients with real-world success.
But we didn’t stop there.
We asked: What if we could make a version of A2M that was even more powerful?
So, we engineered CYT-108 — a recombinant (lab-made) variant designed to outperform natural A2M in both potency and consistency. It’s the next generation of precision OA therapy — optimized for industrial scale, regulatory approval, and maximum efficacy.
🧬 Act III: Proof in the Models
Preclinical studies showed CYT-108 reduced cartilage destruction by up to 57% in animal models — significantly more than natural A2M. It also decreased inflammation, protected bone, and restored healthy cartilage markers like Type II Collagen.
In other words, CYT-108 didn’t just work — it outperformed everything we’d tried before.
🛣️ Today: Clinical Trials and the Road Ahead
That original spark led us all the way to Phase 1 trials in humans. The trial is now complete — with no drug-related adverse events reported — and data analysis is underway. If successful, CYT-108 could become the first truly disease-modifying OA drug.
What started with a single question has become a full-blown revolution in cartilage preservation science.
And for our 6,000+ investors?
You were here before the rest of the world caught on.
Appreciatively,
Joey Bose
President & CEO
Reg A Disclaimer
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. You may obtain a copy of the offering circular here.
